Drugs / IRINOTECAN
IRINOTECAN
also known as
Liposomal Irinotecan · Biotecan · Campto · Camptosar · CPT-11 · DQ-2805 · Irinophore c · Irinotecan anhydrous free-base · +12 more
Small molecule targets TOP1 via inhibition
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07030283 | Dec 2025 → Jul 2028 expected | pancreatic ductal adenocarcinoma | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07595172 | Apr 2026 → Aug 2028 expected | pancreatic ductal adenocarcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06192680 | Apr 2024 → Nov 2025 overdue | colorectal cancer | Harbin Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06184698 | Jan 2024 → Feb 2026 overdue | colorectal cancer | Hebei Medical University Fourth Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06467565 | Dec 2023 → Dec 2024 | pancreatic ductal adenocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05859750 | May 2023 → Jun 2025 overdue | malignant pancreatic neoplasm | Akeso | Recruiting | No outcome recorded |
| Phase 2 | NCT04233866 | Aug 2020 → Mar 2026 overdue | pancreatic adenocarcinoma | ECOG-ACRIN Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03736720 | Jun 2019 → Oct 2022 | pancreatic endocrine carcinoma | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03764553 | May 2019 → Jul 2025 overdue | esophageal cancer | Academic Medical Center - University of Amsterdam | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07585279 | May 2026 → Feb 2031 expected | colorectal cancer | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06571461 | Sep 2024 → Jan 2028 expected | malignant pancreatic neoplasm | CSPC Ouyi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06501664 | Aug 2024 → Nov 2026 expected | esophageal squamous cell carcinoma | Rui-hua Xu, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07474103 | Nov 2025 → Mar 2028 expected | rectum adenocarcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT05382559 Background | Jun 2022 → Dec 2028 expected | cancer | Astellas Pharma Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT03883919 Background | Jul 2019 → Mar 2021 | malignant pancreatic neoplasm | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT07622771 Background | Jun 2026 → Jun 2028 expected | rectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07099794 Background | Aug 2025 → Feb 2029 expected | biliary tract cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07409272 Background | Feb 2026 → Aug 2029 expected | pancreatic adenocarcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06625320 Comparator | Oct 2024 → Jun 2026 overdue | pancreatic ductal adenocarcinoma | Revolution Medicines, Inc. | Active not recruiting | Met primary |
Press releases naming this drug 41 releases
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IRINOTECAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | Biotecan | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | Campto | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | Camptosar | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | CPT-11 | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | DQ-2805 | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | Irinophore c | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | Irinotecan anhydrous free-base | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | IRINOTECAN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | Irinotecan hydrochloride anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | Irinotecan hydrochloride component of xeliri | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | IRINOTECAN HYDROCHLORIDE HYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | Irinotecan hydrochloride trihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | Irinotecan monohydrochloride trihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | Liposomal Irinotecan | “NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous...” PMID 37708904 ↗ Sep 202318“It's a combination of drugs that are already approved to treat pancreatic cancer: Liposomal irinotecan (Nal-IRI or Onivyde®), 5 fluorouracil (5-FU)/leucovorin, and Oxaliplatin.” NCT07030283 ↗ “NALIRIFOX: Oxaliplatin 85 mg/m2, D1; Liposomal irinotecan 60 mg/m2, D1; LV 200 mg/m2; 5-FU 2400 mg/m2, Infusion for 48 hours” NCT07622771 ↗ |
| Known as | Nal-IRI | “It's a combination of drugs that are already approved to treat pancreatic cancer: Liposomal irinotecan (Nal-IRI or Onivyde®), 5 fluorouracil (5-FU)/leucovorin, and Oxaliplatin.” NCT07030283 ↗ |
| Known as | NSC-728073 | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | NSC-759878 | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | Onivyde | “It's a combination of drugs that are already approved to treat pancreatic cancer: Liposomal irinotecan (Nal-IRI or Onivyde®), 5 fluorouracil (5-FU)/leucovorin, and Oxaliplatin.” NCT07030283 ↗ |
| Known as | Onivyde pegylated liposomal (previously known as onivyde) | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Known as | U-101,440E | ChEMBL registry synonym — accepted as the source's own label CHEMBL481 ↗ |
| Action | Inhibit | “DNA topoisomerase I inhibitor” CHEMBL481 ↗ |
| Modality | Small molecule | — CHEMBL481 ↗ |
| Route | Intravenous | “Given IV” NCT03736720 ↗ |
| Target | TOP1 | “DNA topoisomerase I inhibitor” CHEMBL481 ↗ |